Alyeska Investment Group L.P. Purchases Shares of 378,318 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Alyeska Investment Group L.P. acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 378,318 shares of the company's stock, valued at approximately $156,412,000. Alyeska Investment Group L.P. owned approximately 0.46% of IDEXX Laboratories as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. United Capital Financial Advisors LLC raised its holdings in shares of IDEXX Laboratories by 0.9% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after acquiring an additional 22 shares during the period. Cranbrook Wealth Management LLC boosted its position in IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after purchasing an additional 25 shares during the last quarter. Gabelli Funds LLC increased its holdings in IDEXX Laboratories by 5.3% during the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after buying an additional 25 shares during the last quarter. Perigon Wealth Management LLC grew its holdings in IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after purchasing an additional 26 shares during the period. Finally, Summit Trail Advisors LLC boosted its position in IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after purchasing an additional 26 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.98% of the company's stock.

Analyst Ratings Changes

IDXX has been the topic of several analyst reports. Piper Sandler increased their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Barclays upped their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Finally, Morgan Stanley lifted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $524.75.

IDEXX Laboratories Trading Down 0.3 %

NASDAQ IDXX traded down $1.36 during trading hours on Tuesday, reaching $473.71. The company's stock had a trading volume of 890,088 shares, compared to its average volume of 646,542. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market cap of $38.39 billion, a P/E ratio of 44.40, a P/E/G ratio of 3.41 and a beta of 1.52. The firm has a fifty day simple moving average of $419.61 and a 200-day simple moving average of $428.18.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same period last year, the company earned $2.71 EPS. IDEXX Laboratories's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.